PAGSEG Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? PAGSEG Inc trades at $10.95 (market cap $2.94B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.39 (market cap $2.27B). The key difference: PAGSEG Inc is the larger of the two by market cap, and PAGSEG Inc pays a 10.49% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| PAGS | SLS | |
|---|---|---|
Market Cap | $2.94B | $2.27B |
Volume | 4,242,708 | 4,179,659 |
Sector | Industrials | Health |
52-Week High | $12.00 | $15.46 |
52-Week Low | $8.44 | $1.39 |
Typical Hold Time | 26 Days | — |
Enterprise Value | $11.02B | $2.14B |
Dividend Yield | 10.49% | — |
Signals from Pluang's Aura AI — not financial advice
PAGS trades at $10.81, up 2.81% today, with a bullish technical signal from moving averages. The stock shows strong valuation metrics with a P/E of 7.1 and P/S of 0.74, supported by a 10.45% net income margin and recent earnings beats. A dividend of $0.28 is scheduled for September 2026, enhancing income appeal. Revenue growth remains steady, with 2026 guidance maintained despite a challenging macro environment.
Outlook is positive with analyst consensus at Buy (62.5%) and a $10.70 price target, though risks include elevated credit losses and Brazilian interest rate volatility. The stock's low valuation and dividend yield present a value opportunity, but investors must monitor execution on credit quality and banking growth.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →